SV

Street Verdict

Analyst Scorecard

A record of what Milind Karmarkar said publicly, with the source. Not advice.

Pending — not yet graded
“Bullish on the Indian Pharma sector, despite global de-globalisation and tariff threats. He believes that while India is a large supplier to the United States, the US also depends on Indian pharma, suggesting there will be no significant tariff implications for the sector.”
Nifty PharmaBullishCalled 24 Feb 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Milind Karmarkar’s full track record